Pharvaris (PHVS) Reports 83% Lower HAE Attack Rate Versus Placebo
Pharvaris (PHVS) reported that its drug deucrictibant XR reduced HAE attack rates by 83% versus placebo in a Phase 3 trial. The trial met all primary and secondary endpoints, with 45% of participants attack-free over 24 weeks. No serious adverse events were reported.


